[The dilemma of anticoagulant therapy in coronary heart disease]

[The dilemma of anticoagulant therapy in coronary heart disease] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[The dilemma of anticoagulant therapy in coronary heart disease] Abstract Text:

E A Loeliger,

[The dilemma of anticoagulant therapy in coronary heart disease] Publishing Authors By Initials

EA Loeliger,

For similar cardiovascular system: blood vessels: veins research abstracts see: cardiovascular system: blood vessels: veins research

PUBMED ID PMID:

MEDLINE DATE:

[The dilemma of anticoagulant therapy in coronary heart disease] Journal Published:

PUBLICATION TYPE: Review

Journal: Therapeutische Umschau. Revue thérapeutique

VOLUME: 27

Page Numbers: 157-61

Journal Abbreviation:

ISSN: 0040-5930

DAY: 12

MONTH: Mar

YEAR: 1970

[The dilemma of anticoagulant therapy in coronary heart disease] Information

Number of References: 30

LANGUAGE: fre

NlmUniqueID: 407224

[The dilemma of anticoagulant therapy in coronary heart disease] Keywords Mesh Terms:

KEYWORDS: Veins

MESH TERMS: physiopathology

Chemical & Substance for Abstract: [The dilemma of anticoagulant therapy in coronary heart disease] Information

Substance Name: Placebos

Registry Number: 0

Grant and Affiliation Information for [The dilemma of anticoagulant therapy in coronary heart disease]

AFFILIATION:

Country: SWITZERLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ther Umsch

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The dilemma of anticoagulant therapy in coronary heart disease Related Publications

• A double blind study of phenprocoumon prophylaxis after myocardial infarction.
• An improved Method to continuously monitor the Electrode-Skin Impedance during Bioelectric Measurements.
• Detection of heterozygotes for factor 8, 9, and 12 deficiency.
• Kinetic basis of prothrombin estimation particularly with reference to the rectilinearity of the log-log reference curve.
• Long-term anticoagulant treatment after myocardial infarction.
• Oral anticoagulation after myocardial infarction.
• Pharmacological aspects of vitamin K1. A clinical and experimental study in man.
• Quality control of prothrombin time determinations in the Netherlands.
• Quantitation of circulating fibrinogen breakdown products in intravascular clotting.
• Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency.
• Resolution of Superpositions in EMG Signals using Belief Propagation: Results for the Known Constituent Problem.
• [Control of administration of coumarin preparations in a center for thrombosis treatment.]
• [Inadequate thrombokinase control & the quality of long-acting coumarin therapy.]
• [Methods of controlling the effect of anticoagulants.]
• [The dilemma of anticoagulant therapy in coronary heart disease]
• [The dilemma of anticoagulant therapy in coronary heart disease]